HOME >> BIOLOGY >> NEWS
'Modular' leukemia drug shows promise in early testing

COLUMBUS , Ohio -- A new type of engineered drug candidate has shown promise in treating chronic lymphocytic leukemia in both test tube and early animal tests, a new study shows.

The agent represents a new class of agents called small modular immunopharmaceuticals. Called CD37-SMIP, the agent targets a protein called CD37 on the surface of these leukemia cells.

The study shows that the agent can successfully attach to the protein on the leukemia cells and kill them. The agent works both by triggering the cells' self-destruction and by causing a particular class of immune cells to attack them.

In an animal model, the agent worked equally as well as the drug rituximab, now routinely used to treat chronic lymphocytic leukemia (CLL) patients. Rituximab targets a different protein on leukemia cells.

The study by researchers at the Ohio State University Comprehensive Cancer Center was published online in the journal Blood.

Our findings have significant implications for the treatment of CLL and related malignancies, says principal investigator John C. Byrd, director of the hematologic malignancies program at Ohio State 's James Cancer Hospital and Solove Research Institute.

Overall, Byrd says, the findings indicate that this could be an effective agent for treating CLL and other malignancies, such as non-Hodgkin's lymphoma and acute lymphoblastic leukemia when they have expression of the CD37 protein.

The laboratory portion of the study used CLL cells from patients, laboratory-grown non-Hodgkin's lymphoma cells and acute lymphocytic leukemia cells.

This research showed that the agent kills leukemia cells directly by triggering their self-destruction through the process of apoptosis.

The study also found that this self-destruction happens differently from how other drugs cause apoptosis. Most drugs cause cells to self-destruct by triggering a cell mechanism that requires en
'"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University
28-Jun-2007


Page: 1 2

Related biology news :

1. Adult survivors of childhood leukemia exercise less, worsening high risk for obesity and illness
2. Scientists gain important insights into acute promyelocytic leukemia
3. Researchers discover inherited mutation for leukemia
4. Inherited genes linked to toxicity of leukemia therapy
5. Unstable leukemia stem cells may predispose patients to drug resistance
6. Tree rings show elevated tungsten coincides with Nevada leukemia cluster
7. Cancer scientists create human leukemia process to map how disease begins, progresses
8. Antioxidant found in many foods and red wine is potent and selective killer of leukemia cells
9. Knocking out survival protein could aid leukemia treatment
10. Massey researchers induce cell death in leukemia
11. Progress toward a targeted therapy for a specific form of leukemia

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/20/2018)... ... 2018 , ... Thanks to its long-standing expertise in ID reader development and ... as the company now proposes a full range of readers able to satisfy all ... can be used by professionals either in a fixed location or on the move ...
(Date:11/20/2018)... POWAY, Calif. (PRWEB) , ... November 20, 2018 , ... ... disease very early on. Before he was a year old, his mom, Rebecca, ... She had him examined by her veterinarian and her suspicions were confirmed: Jack ...
(Date:11/16/2018)... ... 16, 2018 , ... Earthres Group, Inc., (EARTHRES) Vice President, ... (IBWA’s) IBWA/Shayron Barnes-Selby Advocacy Award at the IBWA Annual Business Conference in New ... IBWA contributor Shayron Barnes-Selby, is awarded to an individual or organization whose advocacy ...
Breaking Biology News(10 mins):
(Date:11/13/2018)... CLARA, Calif. (PRWEB) , ... November 13, 2018 , ... ... its Beijing Office in China. With the increasingly growing demand for AFM technology in ... research and industrial communities by opening an office in Beijing equipped with Park AFM. ...
(Date:11/9/2018)... ... November 08, 2018 , ... ... States, adopted a machine-learning powered approach to increasing recovery rates by creating a ... Artificially Intelligent Collections (AIC) product developed by NLP Logix, a Jacksonville, Florida-based AI ...
(Date:11/6/2018)... RENO and TAHOE, Nev. (PRWEB) , ... November ... ... update to their native mobile app for clinical trial data collection and management. ... authentication. Now, iPhone users with compatible generation devices can quickly and easily sign ...
(Date:11/5/2018)... ... November 05, 2018 , ... ... 2Blades’ Transcription Activator Like (TAL) effector code technology for applications in advancing research ... the technology in plants. Since its discovery in 2009, the efficacy of TAL effector-based ...
Breaking Biology Technology:
Cached News: